Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MacroGenics, Inc.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
At nearly $194,000, the wholesale acquisition cost for Tzield came in above analysts’ $100,000-$115,000 estimates, but payer pushback is not expected as the drug faces no competition.
The company has eight lung cancer trials running and plans for nine by the end of the year, including five with Trodelvy alone. Gilead is also looking ahead to an FDA verdict on lenacapavir.
MacroGenics believes its next-gen anti-CD123 candidate MGD024 has a potentially favorable toxicity profile, as other bispecifics with the same target have floundered. But it lacks the cash to advance on its own.
- Drug Delivery
- Drug Discovery Tools
- Other Names / Subsidiaries
- Raven Biotechnologies